Hikal Q4 Results
- BSE: 524735
- NSE: HIKAL
- ISIN: INE475B01022
- Sector: Biotechnology & Drugs
BSE
176.40
-1.60 (-0.90%)
-1.60 (-0.90%)Volume6.45 K
Updated: Thu 11 Jun, 2026 | 15:29:46
NSE
176.15-2.16 (-1.21%)
-2.16 (-1.21%)Volume1.40 L
Updated: Thu 11 Jun, 2026 | 15:40:16
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
- Total Income₹519.40 Cr.(-5.97%)
- Operating Profit₹16.30 Cr.(-80.98%)
- Profit After Tax₹14.40 Cr.(-71.31%)
- Operating Margin3.14%(-79.77%)
Note: Comparison is on YoY basis
Quarterly - Hikal Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 26 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 503.10 | 490.80 | 2.51% | 451.98 | 7.80% |
| Depreciation/ Amortization | 42.00 | 41.20 | 1.94% | 32.34 | 11.41% |
| Operating Income | 16.30 | 3.50 | 365.71% | 62.12 | -80.98% |
| Net Income | 14.40 | -5.90 | 0.00% | 33.97 | -71.31% |
| Other Operating Expenses Total | 130.20 | 109.00 | 19.45% | 121.61 | -2.40% |
| Net Income Before Taxes | 8.30 | -9.20 | 0.00% | 47.33 | -87.85% |
| Total Revenue | 519.40 | 494.30 | 5.08% | 514.10 | -5.97% |
| Selling/ General/ Admin Expenses Total | 67.20 | 70.60 | -4.82% | 63.78 | 5.99% |
| Diluted Normalized EPS | 3.66 | 1.53 | 139.13% | 2.75 | -10.39% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.